INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) a annoncé les résultats positifs de l'étude de phase 3 VIVID-1 sur le ...
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly reported first-quarter adjusted profit that topped Wall Street's expectations. The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and ...
Drugmaker boosts full-year sales and profit guidance, but supply worries remain in focus Eli Lilly & Co. shares gained 4.5% Tuesday morning after the company reported first-quarter profit that ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its ...
La performance et les perspectives de l'action Eli Lilly sont donc considérées comme stables par Jefferies, les commentaires de l'analyste soulignant la confiance dans la capacité de l'entreprise à ...
Walmart raised its full-year forecast and reported better-than-expected quarterly results on Thursday, betting that easing ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales ...